Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00619684 · OUTCOME

Overall Survival

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant · Source last updated 2017-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
At 1 and 2 years after starting treatment with lenalidomide

What was measured

Kaplan-Meier estimate of survival

Analysis population: Patients enrolled on trial who received lenalidomide therapy.

Groups in this outcome

Treatment (Lenalidomide)

Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity. lenalidomide: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Lenalidomide)18

Reported measurements

Percent Overall Survival at 1 year
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)71Not reported4387Not reported
Percent Overall Survival at 2 years
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)58Not reported3178Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        43
        upper Limit
        87
        value
        71
    title
    Percent Overall Survival at 1 year
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        31
        upper Limit
        78
        value
        58
    title
    Percent Overall Survival at 2 years
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
Kaplan-Meier estimate of survival
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity. lenalidomide: Given PO
    id
    OG000
    title
    Treatment (Lenalidomide)
param Type
NUMBER
population Description
Patients enrolled on trial who received lenalidomide therapy.
reporting Status
POSTED
time Frame
At 1 and 2 years after starting treatment with lenalidomide
title
Overall Survival
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice